Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies.

Edoardo MidenaMark GilliesTodd A KatzCarola MetzigChengxing LuYuichiro Ogura

Published in: Journal of ophthalmology (2018)

Post hoc analyses of VIVID-DME and VISTA-DME demonstrated the benefits of intravitreal aflibercept treatment in DME patients with baseline CRT < 400 μm and ≥400 μm. This trial is registered with NCT01331681 and NCT01363440.

Keyphrases

optical coherence tomography
diabetic retinopathy
clinical trial
vascular endothelial growth factor
age related macular degeneration
heart failure
study protocol
phase iii
left ventricular
phase ii
replacement therapy